Rotavirus Vaccine
Rotavirus gastroenteritis · Severe dehydration · Rotavirus-associated encephalopathy
Rotavirus is the leading cause of severe diarrheal disease in infants and young children worldwide. Before vaccination, it caused ~450,000 child deaths annually globally and ~60,000 hospitalizations per year in the US. By age 5, virtually every child worldwide had been infected at least once. The disease progresses rapidly to severe dehydration in infants.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Rotavirus is the leading cause of severe diarrheal disease in infants and young children worldwide. Before vaccination, it caused ~450,000 child deaths annually globally and ~60,000 hospitalizations per year in the US. By age 5, virtually every child worldwide had been infected at least once. The disease progresses rapidly to severe dehydration in infants.
Rotavirus gastroenteritis causes profuse watery diarrhea (up to 20 episodes/day), vomiting, fever, and severe dehydration that can become life-threatening within hours in infants. Hospitalized children require IV fluids. In low-income countries, rotavirus is a leading killer. Even in the US, the disease causes enormous parental anxiety, missed work, and healthcare utilization. Rare neurological complications (encephalopathy, seizures) occur.
🛡️ Vaccine Effectiveness
Protection highest in first 2 years of life — the highest-risk period. Immunity wanes but natural boosting from exposure may maintain some protection. No booster recommended.
Vaccinated children can still get rotavirus but illness is milder. Significant reduction in hospitalizations and medical visits even when infection occurs.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
First dose must be given before 15 weeks of age. Series must be completed by 8 months. Do not start if child is older than 15 weeks (intussusception risk).
⚖️ Benefits vs. Considerations
✓ Benefits
- Essentially universal childhood exposure means this vaccine benefits nearly every child
- Dramatic reduction in hospitalizations (86% in USA post-introduction)
- Oral administration — no injection required, reducing infant distress
- Critical protection during the highest-risk period (0–2 years) when dehydration is most dangerous
- Global child mortality benefit is enormous (hundreds of thousands of deaths prevented annually)
↕ Considerations
- Relatively newer vaccine (19 years) — long-term data still accumulating compared to older vaccines
- Real intussusception risk (~1.5–5 per 100,000) — requires parent counseling
- VE against any infection (~74%) lower than some other pediatric vaccines
- Strict age limits: cannot start series after 15 weeks of age
- Some immunocompromised infants cannot receive the live oral vaccine
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Some pediatric gastroenterologists argue that in high-income countries with good medical infrastructure (where IV rehydration is readily available), the severity of rotavirus in otherwise healthy infants is manageable, and the intussusception risk (though small) deserves more prominent discussion in parent counseling (Yen et al., 2011).
- The original RotaShield vaccine was withdrawn in 1999 due to intussusception (~1 per 10,000). Current vaccines have a substantially lower rate, but critics argue that the FDA and CDC should be more transparent with parents about this class effect rather than presenting the current vaccines as though the RotaShield history doesn't exist.
- In low-income countries, the VE of rotavirus vaccines has been lower (50–65%) than in high-income countries (85–95%), possibly due to interference from co-administered oral poliovirus vaccine or nutritional status. This raises equity questions about global recommendations (Patel et al., 2012).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- The exact magnitude of the intussusception risk varies between studies and settings — not fully resolved
- Whether the vaccine's benefit is equivalent in high-income settings with universal access to IV rehydration vs. low-income settings
- Long-term impact on natural rotavirus immunity development — whether vaccinated children have different adult immunity patterns
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.